Accelerate Diagnostics, Inc. Securities Litigation
On or around 09/13/2017 (Other)
Filing Date: March 19, 2015
According to the law firm press release, the lawsuit alleges Defendants misrepresented and/or failed to disclose to investors that Accelerate Diagnostics’ main product the ID/AST system, formally known as the BACcel system, requires a positive blood culture to diagnose pathogens in a blood sample. When the truth was revealed to investors, the price of Accelerate Diagnostics securities fell, damaging investors.
On January 28, 2016, the Court issued an Order granting Defendants' Motion to Dismiss and dismissing this action with prejudice. On February 26, Plaintiff filed a Notice of Appeal of this decision. On September 13, 2017, the Appeal was dismissed.
Company & Securities Information
Defendant: Accelerate Diagnostics, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: AXDX
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Brian Rapp, et al. v. Accelerate Diagnostics, Inc., et al.